The FDA has announced a public advisory committee meeting later this summer to consider moving specific peptides to the 503A bulks list[1], which could reopen the door for licensed compounding pharmacies to prepare them
However, it remains a subject of intense investigation in cosmetic science and dermatology for potential future applications in topical formulations.
European Neurology (PubMed) Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients (double-blind study) CDC Vaccine administration: subcutaneous route (angle/site guidance) NCBI Bookshelf Best practices for injection (asepsis, preparation, and administration) Subcutaneous Drug Injection Review (PMC) Pharmacologic considerations of the subcutaneous route Related research, protocols, and guides Explore the available research context, protocol variants or comparisons, and practical guides
The announcement was widely interpreted as a signal that the FDA under the new administration would take a more permissive stance toward peptide compounding than the 2023 Pharmacy Compounding Advisory Committee position, which had placed BPC-157 firmly in Category 2 (substances the FDA had concerns about for compounding use)
Whether you're dealing with age-related cognitive issues or simply looking to enhance your cognitive performance, Dihexa offers a promising solution
Natural Killer (NK) cell cytotoxicitya vital component of the innate immune system's ability to fight off viral pathogens and clear damaged cellswas elevated by up to 400% after just two weeks